Home

CRISPR Therapeutics AG - Common Shares (CRSP)

43.49
+1.12 (2.64%)

Crispr Therapeutics is a biopharmaceutical company that focuses on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing technology

The company aims to harness the potential of genetic editing to treat various conditions, including genetic disorders, cancer, and autoimmune diseases. Through a combination of innovative research and strategic collaborations, Crispr Therapeutics is dedicated to advancing its pipeline of therapies and ultimately improving patient outcomes and quality of life.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close42.37
Open42.64
Bid43.51
Ask43.84
Day's Range42.42 - 43.94
52 Week Range36.52 - 79.33
Volume1,399,819
Market Cap3.43B
PE Ratio (TTM)-9.998
EPS (TTM)-4.4
Dividend & YieldN/A (N/A)
1 Month Average Volume2,654,101

News & Press Releases

Cathie Wood's Ark Invest Continues To Load Up On Tempus AI, Dumps Bitcoin-Focused Block In Tech Meltdown Aftermathbenzinga.com
On Tuesday, Cathie Wood‘s Ark Invest executed notable trades, including significant activity involving Tempus AI Inc. (NASDAQTEM), Block Inc. NYSE:XYZNYSEXYZ)
Via Benzinga · March 11, 2025
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Whyfool.com
Via The Motley Fool · February 28, 2025
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.fool.com
Via The Motley Fool · February 28, 2025
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Streetfool.com
Via The Motley Fool · February 24, 2025
Market Whales and Their Recent Bets on CRSP Optionsbenzinga.com
Via Benzinga · February 20, 2025
This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesdaybenzinga.com
Via Benzinga · February 18, 2025
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?benzinga.com
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)
Via Benzinga · February 16, 2025
The Ultimate Healthcare Stock to Buy With $500 Right Nowfool.com
Via The Motley Fool · February 14, 2025
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridaybenzinga.com
Via Benzinga · February 14, 2025
This Informatica Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Fridaybenzinga.com
Via Benzinga · February 14, 2025
This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Fridaybenzinga.com
Via Benzinga · February 14, 2025
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesdayfool.com
Via The Motley Fool · February 12, 2025
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · February 12, 2025
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.investors.com
The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers.
Via Investor's Business Daily · February 11, 2025
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Movefool.com
Via The Motley Fool · February 10, 2025
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?fool.com
Via The Motley Fool · February 2, 2025
Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Robloxbenzinga.com
Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV.
Via Benzinga · January 31, 2025
My Top 5 Stocks to Buy in Early 2025fool.com
Via The Motley Fool · January 23, 2025
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.
Via MarketBeat · January 23, 2025
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseasesbenzinga.com
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
Via Benzinga · January 22, 2025
3 Unstoppable Stocks to Buy in 2025fool.com
Via The Motley Fool · January 18, 2025
Cathie Wood's Ark Invest Is Betting Big On This AI Darling And No It's Not Nvidiabenzinga.com
Ark Invest made significant trades involving Tempus AI, CRISPR Therapeutics, UiPath, Roblox, Reddit, Accolade, and Ibotta. ARKG and ARKK funds bought shares, while ARKW and ARKF funds sold shares.
Via Benzinga · January 18, 2025
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lowsfool.com
Via The Motley Fool · January 16, 2025
My 10 Top Stocks to Buy to Start the New Year Off Rightfool.com
Via The Motley Fool · January 16, 2025
Vertex's Pain Drug: Big Pharma's Next Major Success?
Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.
Via MarketBeat · January 16, 2025